We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2019 to Apr 2024
By Razak Musah Baba
LONDON--GlaxoSmithKline PLC (GSK.LN), Fondazione Telethon and Ospedale San Raffaele have submitted E.U. regulatory submission for gene therapy to treat rare disease ADA-SCID.
The submission is for a marketing application to the European Medicines Agency for a gene therapy (GSK2696273) to treat patients with a rare disease. Adenosine deaminase (ADA) deficiency is an inherited disorder that causes severe combined immunodeficiency syndrome (SCID). No suitable human leukocyte antigen (HLA)-matched related stem cell donor is available.
ADA-SCID is an incredibly rare disease in which patients cannot make lymphocytes (a type of white blood cell) and as a result have a severely deficient immune system.
GSK2696273 is an investigational gene therapy which is not approved for use anywhere in the world.
The marketing application follows on from a strategic alliance formed in 2010 between GSK, Ospedale and Telethon.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
